About VORANIGO®
A new treatment option for your patients with IDH1/2-mutant glioma
The FIRST and ONLY oral IDH inhibitor indicated in the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation*,1–3
VORANIGO® (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.
Treatment with VORANIGO® should be initiated following confirmation of an IDH1 or IDH2 mutation through a validated test.
a WHO 2016, 2021 grading system.
Mechanism of action: An inhibitor of IDH1 and IDH2 enzymes†,1
VORANIGO®:
- Inhibited IDH1 and IDH2 wild type and variants in vitro and in vivo tumour models expressing IDH1 or IDH2 proteins
- Decreased 2-HG production and may restore cellular differentiation
VORANIGO® decreases 2-HG tumour concentrations in patients with IDH1 or IDH2 mutated glioma.
Adapted from the VORANIGO® Product Monograph.
VORANIGO® resources
VORANIGO® information leaflet
An overview of VORANIGO® in the treatment of IDH1/2-mutant glioma, including efficacy and safety data, as well as dosing and administration information.
WHO: World Health Organization; mIDH1/2: mutant IDH1/2; 2H-G: 2-hydroxyglutarate
*Comparative clinical significance has not been established.
†Clinical significance is unknown.
References:
- VORANIGO® Product Monograph. Servier Canada. August 27, 2024.
- Mellinghoff IK et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589–601.
- Data on file. Servier Canada Inc.
Stay Connected with Servier Canada
Stay up to date on disease information, treatment options, our products, and patient support programs.